New combo therapy aims to stop heart damage in kids with kawasaki disease
NCT ID NCT04747847
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of atorvastatin and anakinra in 5 children with Kawasaki disease who had coronary artery abnormalities. The goal was to see if these drugs could safely reduce artery inflammation and prevent future heart problems. The study focused on safety and how well the children tolerated the treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAWASAKI DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Diego
San Diego, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to shield Children's hearts from kawasaki disease
- Could a once-daily pill replace warfarin for kids with rare heart aneurysms?
- Kawasaki Kids' hearts under the microscope 5 years later
- Massive study aims to crack the code on Kids' medications
- Could a cholesterol drug help Kids' hearts after kawasaki disease?
- New study aims to uncover hidden danger in kawasaki disease